Epidemiologic trends in the utilization, demographics, and cost of bone morphogenetic protein in spinal fusions

被引：15

作者：

Louie P.K. ^{[1
]}

Hassanzadeh H. ^{[1
]}

Singh K. ^{[1
]}

机构：

[1] Department of Orthopaedic Surgery, Midwest Orthopaedics at Rush, Rush University Medical Center, Chicago, IL 60612

来源：

Current Reviews in Musculoskeletal Medicine | 2014年 / 7卷 / 3期

关键词：

Anterior cervical fusion; Anterior lumbar interbody fusion; Bone morphogenetic protein; Epidemiology; Food and Drug Administration; Posterior lumbar fusion; Spinal fusion;

D O I：

10.1007/s12178-014-9222-2

中图分类号：

学科分类号：

摘要：

Bone morphogenetic protein (BMP) utilization as an adjunct for spinal arthrodesis has gained considerable momentum among spine surgeons. Despite carrying Food and Drug Administration approval for only single level anterior lumbar interbody fusion from L4-S1, the majority of BMP administration is in "off label" settings. Over the last decade, BMP utilization has increased in all facets of spine surgery with the only exception being the anterior cervical spine, in which a downward trend resulted following the 2008 Food and Drug Administration warnings. The future application of BMP in spinal fusion, especially in anterior cervical fusions, will need to be further clarified in terms of efficacy, complications, and cost-effectiveness. © 2014 Springer Science+Business Media.

引用

页码：177 / 181

页数：4

共 34 条

[1]

Buttermann G.R., Prospective nonrandomized comparison of an allograft with bone morphogenic protein versus an iliac-crest autograft in anterior cervical discectomy and fusion, Spine J, 8, pp. 426-435, (2008)

[2]

Cahill K.S., Chi J.H., Day A., Claus E.B., Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures, JAMA, 302, pp. 58-66, (2009)

[3]

Glassman S.D., Carreon L.Y., Djurasovic M., Et al., RhBMP-2versus iliac crest bone graft for lumbar spine fusion: A randomized, controlled trial in patients over sixty years of age, Spine, 33, pp. 2843-2849, (2008)

[4]

Ong K.L., Villarraga M.L., Lau E., Carreon L.Y., Kurtz S.M., Glassman S.D., Off-label use of bone morphogenetic proteins in the United States using administrative data, Spine, 35, pp. 1794-1800, (2010)

[5]

Burkus J.K., Heim S.E., Gornet M.F., Zdeblick T.A., Is INFUSE bone graft superior to autograft bone? An integrated analysis of clinical trials using the LT-CAGE lumbar tapered fusion device, J Spinal Disord Tech, 16, pp. 113-122, (2003)

[6]

Matthews S.J., Biological activity of bone morphogenetic proteins (BMP's), Injury, 36, SUPPL. 3, (2005)

[7]

Axelrad T.W., Einhorn T.A., Bone morphogenetic proteins in orthopaedic surgery, Cytokine Growth Factor Rev, 20, pp. 481-488, (2009)

[8]

Kim D.H., Rhim R., Li L., Et al., Prospective study of iliac crest bone graft harvest site pain and morbidity, Spine J, 9, pp. 886-892, (2009)

[9]

Kurz L.T., Garfin S.R., Booth Jr. R.E., Harvesting autogenous iliac bone grafts. A review of complications and techniques, Spine, 14, 12, pp. 1324-1331, (1989)

[10]

InFUSE™ Bone Graft/LT-CAGE™ Lumbar Tapered Fusion Device - P000058, (2002)

← 1 2 3 4 →